Selux Diagnostics Integrated Symposium at ECCMID 2020
April 18 @ 13:30 - 15:30 CEST
Read the current statement regarding the ECCMID conference in relation to the COVID-19 outbreak on eccmid.org
Description: While the past decade has seen a revolution in rapid pathogen identification, similar improvements in blood culture and phenotypic antimicrobial susceptibility testing have not yet been achieved. This session will explore the scientific and technological challenges faced by diagnostic platforms and present novel developments in related testing.
Prof. Patrick Plésiat, PharmD, PhD
Professor of Medical Microbiology, University of Franche-Comté;
Head of Bacteriology Department, University of Franche-Comté Hospital, (Besançon, France);
Head of the French National Reference Center for Antibiotic Resistance (NRC-AR)
Susan E. Sharp, PhD, D(ABMM), F(AAM)
Scientific Director, Copan Diagnostics, Inc. (Murrieta, CA, USA);
Past President, American Society for Microbiology (Washington, D.C., USA)
Lecture 1: Organism Identification: A Success Story – The Infectious Diseases Revolution Heralded by PCR and MALDI-TOF Mass Spectrometry
Up until about two and a half decades ago, clinical microbiology was a practice carried out as it had been in the first half of the 1900’s, based largely on culture and with tedious methods applied to identify grown microorganisms. Today, we are in the midst of a revolution in clinical microbiology diagnostics, heralded by such technologies as nucleic acid amplification tests and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. This presentation will summarize changes over the last quarter century, and their impact on laboratory practice and patient care, as a prelude to anticipating what is to come in diagnostic medical microbiology.
Prof. Robin Patel, MD(CM), D(ABMM), FIDSA, FACP, F(AAM)
Chair, Division of Clinical Microbiology; Director, Infectious Diseases Research Laboratory; Elizabeth P. and Robert E. Allen Professor of Individualized Medicine; Professor of Medicine; Professor of Microbiology at Mayo Clinic (Rochester, Minnesota, USA);
President, American Society for Microbiology (Washington, D.C., USA)
Lecture 2: Antimicrobial Susceptibility Testing: What Does It Mean to Go Fast?
Traditional antimicrobial susceptibility testing requires isolation of an organism in pure culture, at a concentration equivalent to a 0.5 McFarland standard, and incubation for 18+ hours. This presentation will explore how we can break out of this paradigm to provide rapid, at point of need, susceptibility testing for bacterial pathogens.
Prof. Romney Humphries PhD, D(ABMM), M(ASCP)
Chief Scientific Officer, Accelerate Diagnostics, Inc. and Professor, University of Arizona (Tucson, Arizona, USA)
Lecture 3: Blood Culture: A Short History of Current Methods and Future Needs
This talk will begin with a brief history of blood cultures and blood culture technology. It will then discuss advances made in recent decades leading to the current state of the art. It will conclude with current shortcomings and future needs.
Prof. Melvin P. Weinstein, MD, FIDSA, FACP, F(AAM)
Professor of Medicine and Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School (New Brunswick, New Jersey, USA)
Lecture 4: Rapid Diagnostics’ Value: A Critical Integration with Clinical Care
A more rapid diagnosis is always welcome and is often the clinical microbiology laboratory’s top request. Yet, in order to have clinical utility results must be medically actionable and tightly coordinated with its order. This presentation will discuss how one might build a coherent approach, from the “sample in” to the “proposed medical action out.”
Prof. Jacques Schrenzel, MD
Director of the Clinical Microbiology Laboratory and Founder and Director of the Genomic Research Laboratory Service, Division of Infectious Diseases and Laboratory Medicine, Geneva University Hospitals (Geneva, Switzerland)
Lecture 5: New Approaches to Overcome the Speed/Performance Tradeoff
Rapid detection technologies face significant engineering and scientific obstacles to meeting accuracy and cost metrics demanded by clinical laboratories. This talk will discuss key trade-offs and solutions for rapid technologies, with a specific focus on blood culture and AST.
Dr. Eric Stern PhD
Chief Technology Officer and Co-Founder, Selux Diagnostics, Inc. (Charlestown, Massachusetts, USA)
Lecture 6: Panel Discussion on Rapid Diagnostics
Participation by all speakers
All ECCMID 2020 integrated symposia are open to all ECCMID delegates. Please fill out the form below to let us know that you are interested and plan to attend the Selux Diagnostics integrated symposium during the ECCMID 2020 conference. For more information, visit: www.eccmid.org